Two independent research teams have reached the same conclusion: early aortic valve replacement (AVR)—whether TAVR or SAVR—offers better outcomes than clinical surveillance (CS) in asymptomatic severe aortic stenosis (AS).
Analyzing data from 1,427 patients across four RCTs (RECOVERY, AVATAR, EVoLVeD, EARLY TAVR), both studies found early AVR significantly reduced stroke risk and unplanned hospitalizations, though no significant difference in all-cause mortality was observed. The average follow-up was 4.1 years.
Researchers emphasized that a proactive AVR approach may better prevent complications, challenge current guideline practices, and help identify patients who benefit most from early intervention.
Follow MEDWIRE.AI for more cardiovascular treatment insights.
